EDNRB產(chǎn)品信息
英文名稱：Endothelin receptor type B
中文名稱：內(nèi)皮素B受體
靶點別稱：EDNRB
物種：Human
屬性：Protein
標(biāo)記：Unconjugated/GFP Fusion
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
制劑（Formulation）
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
運輸（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存儲（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 12 months under sterile conditions.
EDNRB分子背景
Endothelin Receptor B (EDNRB) is a type of G protein-coupled Receptor with the N-terminus located outside the cell. It's widespread in the human body. EDNRB binds to ET and transmits information into the cell through the intracellular Ca2+ phospholipid-dependent protein kinase second messenger system, which promotes the rapid release of calcium in the endoplasmic reticulum and sarcoplasmic reticulum, resulting in the rapid increase of intracellular calcium concentration. Endothelin exerts its biological effects through its receptor (ETR). Endothelin and ETR constitute the endothelin axis. Endothelin axis has pro-tumor effects in various tumors including malignant melanoma (MM), including promoting tumor growth, anti-apoptosis, promoting angiogenesis and promoting tumor metastasis.
關(guān)鍵字： EDNRB;EDNRB蛋白;EDNRB重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。